Verizon readies for 2024 wildfire season
April 24, 2024 11:00 ET
|
Verizon Sourcing LLC
IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- As Wildfire Awareness Month approaches in May, Verizon is committed to maintaining the safety and connectivity of communities, businesses, and...
Verizon readies for 2024 wildfire season
April 24, 2024 11:00 ET
|
Verizon Sourcing LLC
IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- As Wildfire Awareness Month approaches in May, Verizon is committed to maintaining the safety and connectivity of communities, businesses, and...
Verizon readies for 2024 wildfire season
April 24, 2024 11:00 ET
|
Verizon Sourcing LLC
IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- As Wildfire Awareness Month approaches in May, Verizon is committed to maintaining the safety and connectivity of communities, businesses, and...
Verizon readies for 2024 wildfire season
April 24, 2024 11:00 ET
|
Verizon Sourcing LLC
IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- As Wildfire Awareness Month approaches in May, Verizon is committed to maintaining the safety and connectivity of communities, businesses, and...
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
April 24, 2024 10:30 ET
|
BioXcel Therapeutics
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 ...
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
April 24, 2024 10:09 ET
|
Cullinan Therapeutics, Inc.
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that...
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
April 24, 2024 10:05 ET
|
Regeneron Pharmaceuticals, Inc.
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination...
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:05 ET
|
Werewolf Therapeutics, Inc.
Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) --...
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:02 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective...
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:01 ET
|
Cue Biopharma, Inc.
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...